The costs and expenses are worth it if they allow the company to be properly valued. Clearly Australians don't know how to value biotech. OCC has FDA and EU approvals, a global distribution cash deal with the world leader in dental products, but it is valued less than before it achieved these milestones. It's absurd.
OCC Trading, page-1311
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.5¢ | $49.66K | 129.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20305 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 77938 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |